Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CPS1 | P31327 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035241 | 0.93 | MAPT (0.35) | GAAPOLBMAPTCPS1MEN1 | |
| SCHEMBL5028711 | 0.91 | POLB (0.32) | POLBFFAR1 | |
| SCHEMBL5030915 | 0.88 | GPR139 (0.30) | — | |
| SCHEMBL5030933 | 0.87 | — | — | |
| SCHEMBL14285900 | 0.84 | GAA (0.36) | ATMMTNR1AMTNR1BGAATDP2 | |
| SCHEMBL5030916 | 0.83 | MEN1 (0.32) | GAAMAPTMEN1KMT2A | |
| SCHEMBL14626450 | 0.82 | MTNR1B (0.38) | ATMMTNR1AMTNR1BGAATDP2 | |
| SCHEMBL5033157 | 0.82 | HTT (0.36) | MTNR1BPOLBMAPTCPS1MEN1 | |
| SCHEMBL14285919 | 0.80 | MAPT (0.37) | POLBMAPTCPS1MEN1KMT2A | |
| SCHEMBL14626449 | 0.78 | MAPT (0.36) | POLBMAPTCPS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838500-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7838500-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-7838500-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20090181905-A1 | CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181905-A1 | CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181905-A1 | CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7524822-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-7524822-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| US-7524822-B2 | Crystalline form of 1′-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-28 | — | — | US | disclosed |
| EP-1910391-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | AJINOMOTO CO., INC. (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20070244176-A1 | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244176-A1 | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244176-A1 | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | AJINOMOTO CO., INC. (JP) | 2007-10-18 | — | — | US | disclosed |
| WO-2007080170-A1 | CRYSTALLINE FORM OF 1´-(1-METHYLETHYL)- 4´-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5´-METHYL-1H-PYRAZOL-3´-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007010015-A1 | PROCESSES FOR PREPARING PYRAZOLE-O-GLYCOSIDE DERIVATIVES AND NOVEL INTERMEDIATES OF SAID PROCESSES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080020987-A1 | Processes for preparing pyrazole-O-glycoside derivatives and novel intermediates of said processes | CYP4B1, CYP1B1, CYP11B1 | ATM 3857/4885MTNR1A 3806/4885MTNR1B 3260/4885 |
| US-20090181905-A1 | CRYSTALLINE FORM OF 1' -(1-METHYLETHYL)-4' -[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5' -METHYL-1H-PYRAZOL-3' -O-BETA-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | UGGT1, GANAB, MGAT3 | ATM 4365/4885MTNR1A 1413/4885MTNR1B 1643/4885 |
| US-20070244176-A1 | Crystalline form of 1'-(1-methylethyl)-4'-[(2-fluoro-4-methoxyphenyl)methyl]-5'-methyl-1H-pyrazol-3'-O-beta-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments | UGGT1, GANAB, MGAT3 | ATM 4365/4885MTNR1A 1413/4885MTNR1B 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.